CVS Health reports progress against goal to reduce suicide attempts among Aetna membersCVS Health has seen a 15.7% reduction in suicide attempts among Aetna members through March 2022 compared to 2019 baselines. Hikma intros 2 injectablesThe company is offering bortezomib for injection 3.5 mg and ulvestrant injection 250 mg/5 ml. Walgreens Boots Alliance takes full acquisition of Shields Health Solutions WBA is acquiring the remaining 30% stake of Shields (approximately 35% on a fully diluted basis) for approximately $1.37 billion. AAM reacts to Avalere study on generic drug costs The Avalere analysis shows that generic drugs continue to be misplaced on higher formulary tiers, unfairly driving up costs for patients. Watch DSN: Walgreens’ Ramita Tandon highlights company’s clinical trial business Tandon, chief clinical trials officer at Walgreens, discusses the company’s decision to launch its clinical trial business. Bristol Myers Squibb obtains FDA nod for Sotyktu Sotyktu is an oral treatment for adults with moderate-to-severe plaque psoriasis. Bausch Health responds to Norwich Pharmaceuticals’ tentative FDA nod for rifaximin Xifaxan 200 mg is indicated for travelers' diarrhea and currently contributes less than 1% of Salix’s revenues. McKesson to acquire Rx Savings Solutions The acquisition aligns with McKesson’s strategic growth focus by connecting biopharma and payer services to patients, the company said. NACDS to conduct virtual pharmacy voter event with Charlie Cook The NACDS RxIMPACT Votes event will provide information about the 2022 elections and what they expect for the future of pharmacy. Dr. Reddy’s debuts generic Revlimid Dr. Reddy’s is eligible for first to market, 180 days of generic drug exclusivity for lenalidomide capsules in 2.5-mg and 20-mg strengths. First Previous 180 181 182 183 184 Next Last
